Kineret (Anakinra)

Kineret is an Interleukin‑1 receptor antagonist used in a range of inflammatory and autoinflammatory diseases.

• Rheumatoid arthritis: reduces signs and symptoms of disease activity.
• Cryopyrin‑Associated Periodic Syndromes (CAPS): controls recurrent fever and systemic inflammation.
• Neonatal‑onset multisystem inflammatory disease (NOMID): mitigates chronic inflammatory manifestations.
• Systemic juvenile idiopathic arthritis: improves joint function and reduces systemic features.
• Adult‑onset Still's disease: alleviates fever, rash and joint pain.
• Acute gout flares: shortens duration and severity of attacks.

• Anakinra competitively binds to the interleukin‑1 type I receptor, preventing endogenous IL‑1α and IL‑1β from attaching. This blocks IL‑1‑mediated intracellular signaling pathways that drive inflammation, thereby reducing the production of downstream pro‑inflammatory cytokines and acute‑phase reactants.

Kineret may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Injection‑site reactions such as redness, swelling or pain.
• Headache.
• Nausea.
• Upper respiratory tract infection.
• Dizziness.
• Arthralgia.

Serious or Rare Side Effects

• Neutropenia or other significant blood‑count abnormalities.
• Serious infections, including sepsis.
• Anaphylactic or severe allergic reactions.
• Elevated liver enzymes.
• Rare malignancies reported in long‑term use.

Before initiating Kineret, clinicians should evaluate several safety considerations.

• Pregnancy: Category B – use only when the potential benefit justifies the potential risk to the fetus.
• Infection risk: screen for active infections and monitor for new signs during therapy.
• Neutropenia: obtain baseline and periodic complete blood counts.
• Live vaccines: avoid administration while on treatment.
• Renal impairment: dose adjustment may be required in severe cases.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kineret can interact with other agents that affect immune function.

Major Interactions (Avoid)

• Live vaccines: may cause severe infection.
• Concurrent use of other biologic immunosuppressants (e.g., TNF inhibitors): heightened infection risk.
• Cytotoxic chemotherapy: increased immunosuppression.

Moderate Interactions (Monitor Closely)

• Systemic corticosteroids: additive immunosuppressive effect.
• Conventional disease‑modifying antirheumatic drugs (e.g., methotrexate, azathioprine): monitor for infection.
• Antibiotics: adjust therapy if neutropenia develops.